

November 22, 2024

BSE Limited

Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department Exchange Plaza, C-1, Block-G,

Bandra-Kurla Complex,

Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Press Release

Marksans Pharma Limited receives USFDA approval for Loratadine Tablets USP 10 mg.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces the final approval of the Company's Abbreviated New Drug Application (ANDA) for Loratedine Tablets USP 10 mg from USFDA.

They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use.

This product is generic version of Clartin tablet in the same strength of Bayer Healthcare.

Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies.

Thanking you, Yours faithfully For **Marksans Pharma Limited**

Harshavardhan Panigrahi Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The Company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Upper respiratory and Gastroenterological. The Company is marketing these products globally.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: info@marksanspharma.com www.marksanspharma.com